Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression.
The pipeline includes cirmtuzumab, a monoclonal antibody in Phase 1/2 development that inhibits the ROR1 receptor in various hematologic cancers; TK-216, a small-molecule in Phase 1 development that inhibits ETS-family oncoproteins, as a treatment for Ewing sarcoma, a rare pediatric cancer; and a CAR-T therapy that targets ROR1 currently in preclinical development as a potential treatment for solid tumors and hematologic cancers.
Based in San Diego, Oncternal is committed to advancing its pipeline rapidly and efficiently to bring patients a new wave of first-in-class cancer treatments.
Company Details
- Employees
- 10
- Founded
- 2013
- Address
- 12230 El Camino Real,
- Phone
- (858)434-1113
- in****@****nal.com
- Industry
- Biotechnology
- Website
- oncternal.com
- HQ
- San Diego, California
Oncternal Therapeutics Questions
Oncternal Therapeutics's helpline number is (858)434-1113
Oncternal Therapeutics's website is oncternal.com
Oncternal Therapeutics's LinkedIn profile is https://www.linkedin.com/company/oncternal-therapeutics
Oncternal Therapeutics has
10 employees.
View email and phone details for 10
employees at Oncternal Therapeutics.
Oncternal Therapeutics's industry is
Biotechnology
Oncternal Therapeutics's top competitors are
Ventyx Biosciences,
Neurocrine Biosciences,
Bluebird Bio,
Turnstone Biologics,
Shattuck Labs,
Sage Therapeutics,
Athira Pharma,
Relay Therapeutics,
Immunitybio, Inc.,
Mirador Therapeutics.
Oncternal Therapeutics's support email address is info@oncternal.com
Oncternal Therapeutics's categories are Biotechnology
Oncternal Therapeutics's founding year is 2013
